News

CNBC's Investing Club is updating its rating on FedEx Freight following a strong post-spin price run-up. The article is a brief teaser for the club's daily "Homestretch" afternoon update, with no specific rating or price target disclosed in the body. No additional financial details or figures are provided.

Bernstein analysts report that Bitcoin inflows have slowed sharply in 2026, attributing the trend to investors rotating capital toward artificial intelligence-related assets. The note suggests a competitive dynamic between crypto and AI as destinations for speculative and growth-oriented capital. No specific company actions or earnings events are cited; the report reflects a sector-level capital flow observation.

10xResearch argues that Bitcoin's recent price decline is driven by rising inflation concerns rather than selling pressure from Strategy (formerly MicroStrategy). The research firm pushes back on narratives attributing the tumble to Strategy's Bitcoin holdings or activity. Macro inflation dynamics are cited as the primary headwind for the cryptocurrency.

Standard Chartered analyst Geoff Kendrick suggests that Strategy's recent bitcoin sale could signal the beginning of a period of outperformance for ether relative to bitcoin. The call is based on a shift in capital flows and positioning dynamics following the Strategy transaction. No specific price targets or timeframes were provided in the headline coverage.

NYDIG analyst Greg Cipolaro suggests a $1.3 billion block sale of BlackRock's iShares Bitcoin Trust (IBIT) last week was a large directional trader exiting a position, citing the below-market execution price and the willingness to sacrifice millions for immediate liquidity. The sale was notable for its size and discount, pointing to a single large holder rather than a broad market shift. No fundamental change to IBIT or BlackRock's underlying product is implied.

Jefferies analysts project that crypto-related IPOs could generate a market worth up to $1 trillion, driven by a broader wave of asset tokenization. The report frames the opportunity as sector-wide rather than tied to any single company. No specific company actions or confirmed deals are cited in the article.

Eli Lilly's new oral GLP-1 weight-loss drug is reportedly seeing prescription volumes trail Novo Nordisk's oral Wegovy. JPMorgan has initiated coverage on Hims & Hers Health. Regeneron is offering a new hearing-loss therapy at no cost.

Intel stock has surged approximately 66% since March 30, adding over $137 billion in market cap, fueled by a reported AI chip supply partnership with Google and involvement in Elon Musk's Terafab semiconductor project. The stock currently trades at elevated valuations of 904x trailing earnings and 135x forward earnings. Intel is set to report Q1 earnings on April 23, which will be a key test for sustaining the recent rally.